All In Biotech

Drug Trial Radar · NCT05753865

A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)

A Multicenter, Randomized, Double-blind Phase Ш Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)

Last checked: Nov 19, 2026Latest source record: Mar 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 454 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

454

Planned (sponsor's estimate)

Start

May 1, 2023

Primary completion

Sep 1, 2024

Study completion Sep 1, 2024

Sponsor

Sponsor type
Industry
First posted
Mar 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the efficacy and safety in patients with advanced breast cancer treated with SYHX2011 versus paclitaxel for injection (albumin-bound).

Conditions

  • Advanced Breast Cancer

Interventions

  • SYHX2011Drug

    IV infusion, 260 mg/m\^2

  • Paclitaxel for injection (albumin-bound)Drug

    IV infusion, 260 mg/m\^2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) by IRCTime frame: Up to approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.